CONFO
LIVE

Serial Number

97685859

Owner

CONFO THERAPEUTICS NV

Attorney

Maury M. Tepper, III

Filing Date

Nov 21, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CONFO Trademark

Serial Number: 97685859

CONFO is a trademark filed by CONFO THERAPEUTICS NV on November 21, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

CONFO THERAPEUTICS NV (9 trademarks)

TECHNOLOGIEPARK, ZWIJNAARDE 30
GENT 9052 , BE

Entity Type: 32

Confo Therapeutics N.V. (10 trademarks)

Technologiepark,

Entity Type: 98

Trademark Details

Filing Date

November 21, 2022

Registration Date

Not Registered

Published for Opposition

January 7, 2025

Goods & Services

Medical and pharmacological research services; Pharmaceutical drug development services; Laboratory research services relating to pharmaceuticals; Research and development of vaccines and medicines; Scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with G protein-coupled receptors (GPCRs); Design of computer databases; Updating of database software; Data warehousing; Provision of information and data relating to medical research and development; Rendering of computer graphics featuring digital image correction for research and development; Computer graphic design services featuring data and image processing services for making three dimensional models; Non-medical graphic design featuring digital imaging services; Optical imaging for use in research and development of medicines; Imaging via computers for use in research and development of medicines; Graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines

Pharmaceutical and veterinary preparations for use in oncology and in the field of immunology, namely, pharmaceutical and veterinary preparations for treating immune-related diseases; pharmaceutical and veterinary preparations for the treatment of inflammatory diseases and infections and for the treatment of gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological and musculo-skeletal conditions and for the treatment of orphan diseases; chemical and biochemical substances for pharmaceutical and veterinary use in the nature of stabilized protein arrays, namely, small molecules and antibodies for diagnostic purposes for use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections and for the treatment of gastrointestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological and musculo-skeletal conditions and for the treatment of orphan diseases; veterinary products, namely, antibody reagents used for the detection of antigens in cells and tissue for medical purposes; veterinary products, namely, antibody reagents for therapeutic use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections and for the treatment of gastrointestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological and musculo-skeletal conditions and for the treatment of orphan diseases; veterinary products, namely, small molecules in the form of low molecular weight organic compounds; veterinary products, namely, biological preparations for use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections and for the treatment of gastrointestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological and musculo-skeletal conditions and for the treatment of orphan disease

Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substances, namely, antibodies for stabilization of proteins, all the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); Chemical substances for use in the production of drugs; Biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); Proteins for use in science; Chimeric proteins to measure, test and develop compounds and ligands binding to G protein-coupled receptors (GPCRs)

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 3, 2026 GNRN
NON-FINAL ACTION E-MAILED
Feb 3, 2026 GNRT
NON-FINAL ACTION WRITTEN
Feb 3, 2026 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 2, 2026 ZZZX
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 11, 2025 ASGN
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Feb 6, 2025 ERRR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 7, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 7, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 1, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 11, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 19, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 21, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 21, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 21, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 22, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 22, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 23, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 23, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 24, 2023 GNRN
NON-FINAL ACTION E-MAILED
Oct 24, 2023 GNRT
NON-FINAL ACTION WRITTEN
Oct 24, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 1, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 12, 2022 NWOS
NEW APPLICATION ENTERED
Nov 24, 2022 NWAP